within Pharmacolibrary.Drugs.ATC.S;

model S01FA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 8.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Methylscopolamine is a quaternary ammonium derivative of scopolamine, used as an antimuscarinic agent for the treatment of gastrointestinal disorders such as peptic ulcer, and for the reduction of salivation and respiratory secretions. It is less likely to cross the blood-brain barrier compared to scopolamine. Methylscopolamine is approved for use in several countries for these indications, primarily as adjunctive therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult population based on general physicochemical and pharmacological properties of quaternary ammonium antimuscarinics; no direct clinical PK data available in published human studies as of 2024.</p><h4>References</h4><ol><li><p>Salehi, S, et al., &amp; Birkhed, D (2013). Oral rehydration therapy products - a plaque pH study under normal and dry mouth conditions. <i>International dental journal</i> 63(5) 254–258. DOI:<a href=&quot;https://doi.org/10.1111/idj.12041&quot;>10.1111/idj.12041</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24074020/&quot;>https://pubmed.ncbi.nlm.nih.gov/24074020</a></p></li><li><p>Oki, T, et al., &amp; Yamada, S (2007). Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. <i>The Journal of urology</i> 177(2) 766–770. DOI:<a href=&quot;https://doi.org/10.1016/j.juro.2006.09.079&quot;>10.1016/j.juro.2006.09.079</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17222678/&quot;>https://pubmed.ncbi.nlm.nih.gov/17222678</a></p></li><li><p>Oki, T, et al., &amp; Yamada, S (2006). Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion. <i>The Journal of pharmacology and experimental therapeutics</i> 316(3) 1137–1145. DOI:<a href=&quot;https://doi.org/10.1124/jpet.105.094508&quot;>10.1124/jpet.105.094508</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16282521/&quot;>https://pubmed.ncbi.nlm.nih.gov/16282521</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01FA03;
